RGD-binding integrins in head and neck cancers

Hanadi Talal Ahmedah, Laurence H. Patterson, Steven D. Shnyder, Helen M. Sheldrake

Research output: Contribution to journalReview articleResearchpeer-review

6 Citations (Scopus)

Abstract

Alterations in integrin expression and function promote tumour growth, invasion, metastasis and neoangiogenesis. Head and neck cancers are highly vascular tumours with a tendency to metastasise. They express a wide range of integrin receptors. Expression of the αv and β1 subunits has been explored relatively extensively and linked to tumour progression and metastasis. Individual receptors αvβ3 and αvβ5 have proved popular targets for diagnostic and therapeutic agents but lesser studied receptors, such as αvβ6, αvβ8, and β1 subfamily members, also show promise. This review presents the current knowledge of integrin expression and function in squamous cell carcinoma of the head and neck (HNSCC), with a particular focus on the arginine-glycine-aspartate (RGD)-binding integrins, in order to highlight the potential of integrins as targets for personalised tumour-specific identification and therapy.

Original languageEnglish
Article number56
JournalCancers
Volume9
Issue number6
DOIs
Publication statusPublished - 1 Jun 2017

Fingerprint

Head and Neck Neoplasms
Integrins
Neoplasms
Neoplasm Metastasis
Glycine
Blood Vessels
Therapeutics
Growth

Keywords

  • Arginine-glycine-aspartate (RGD)
  • Integrin αv
  • Metastasis
  • Treatment resistance
  • β1
  • β3
  • β6

Cite this

Ahmedah, H. T., Patterson, L. H., Shnyder, S. D., & Sheldrake, H. M. (2017). RGD-binding integrins in head and neck cancers. Cancers, 9(6), [56]. https://doi.org/10.3390/cancers9060056
Ahmedah, Hanadi Talal ; Patterson, Laurence H. ; Shnyder, Steven D. ; Sheldrake, Helen M. / RGD-binding integrins in head and neck cancers. In: Cancers. 2017 ; Vol. 9, No. 6.
@article{45c4e7a908b842e0bb762cec66aead83,
title = "RGD-binding integrins in head and neck cancers",
abstract = "Alterations in integrin expression and function promote tumour growth, invasion, metastasis and neoangiogenesis. Head and neck cancers are highly vascular tumours with a tendency to metastasise. They express a wide range of integrin receptors. Expression of the αv and β1 subunits has been explored relatively extensively and linked to tumour progression and metastasis. Individual receptors αvβ3 and αvβ5 have proved popular targets for diagnostic and therapeutic agents but lesser studied receptors, such as αvβ6, αvβ8, and β1 subfamily members, also show promise. This review presents the current knowledge of integrin expression and function in squamous cell carcinoma of the head and neck (HNSCC), with a particular focus on the arginine-glycine-aspartate (RGD)-binding integrins, in order to highlight the potential of integrins as targets for personalised tumour-specific identification and therapy.",
keywords = "Arginine-glycine-aspartate (RGD), Integrin αv, Metastasis, Treatment resistance, β1, β3, β6",
author = "Ahmedah, {Hanadi Talal} and Patterson, {Laurence H.} and Shnyder, {Steven D.} and Sheldrake, {Helen M.}",
year = "2017",
month = "6",
day = "1",
doi = "10.3390/cancers9060056",
language = "English",
volume = "9",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "6",

}

Ahmedah, HT, Patterson, LH, Shnyder, SD & Sheldrake, HM 2017, 'RGD-binding integrins in head and neck cancers', Cancers, vol. 9, no. 6, 56. https://doi.org/10.3390/cancers9060056

RGD-binding integrins in head and neck cancers. / Ahmedah, Hanadi Talal; Patterson, Laurence H.; Shnyder, Steven D.; Sheldrake, Helen M.

In: Cancers, Vol. 9, No. 6, 56, 01.06.2017.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - RGD-binding integrins in head and neck cancers

AU - Ahmedah, Hanadi Talal

AU - Patterson, Laurence H.

AU - Shnyder, Steven D.

AU - Sheldrake, Helen M.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Alterations in integrin expression and function promote tumour growth, invasion, metastasis and neoangiogenesis. Head and neck cancers are highly vascular tumours with a tendency to metastasise. They express a wide range of integrin receptors. Expression of the αv and β1 subunits has been explored relatively extensively and linked to tumour progression and metastasis. Individual receptors αvβ3 and αvβ5 have proved popular targets for diagnostic and therapeutic agents but lesser studied receptors, such as αvβ6, αvβ8, and β1 subfamily members, also show promise. This review presents the current knowledge of integrin expression and function in squamous cell carcinoma of the head and neck (HNSCC), with a particular focus on the arginine-glycine-aspartate (RGD)-binding integrins, in order to highlight the potential of integrins as targets for personalised tumour-specific identification and therapy.

AB - Alterations in integrin expression and function promote tumour growth, invasion, metastasis and neoangiogenesis. Head and neck cancers are highly vascular tumours with a tendency to metastasise. They express a wide range of integrin receptors. Expression of the αv and β1 subunits has been explored relatively extensively and linked to tumour progression and metastasis. Individual receptors αvβ3 and αvβ5 have proved popular targets for diagnostic and therapeutic agents but lesser studied receptors, such as αvβ6, αvβ8, and β1 subfamily members, also show promise. This review presents the current knowledge of integrin expression and function in squamous cell carcinoma of the head and neck (HNSCC), with a particular focus on the arginine-glycine-aspartate (RGD)-binding integrins, in order to highlight the potential of integrins as targets for personalised tumour-specific identification and therapy.

KW - Arginine-glycine-aspartate (RGD)

KW - Integrin αv

KW - Metastasis

KW - Treatment resistance

KW - β1

KW - β3

KW - β6

UR - http://www.scopus.com/inward/record.url?scp=85020036879&partnerID=8YFLogxK

U2 - 10.3390/cancers9060056

DO - 10.3390/cancers9060056

M3 - Review article

VL - 9

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 6

M1 - 56

ER -